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Background: In allergic contact dermatitis (ACD) previously sensitized T cells cause skin 
damage. If an ubiquitous allergen such as nickel is involved, no effective treatment is avail- 
able. Down-regulation of this allergic response has been described after antigen presentation 
in the absence of adequate costimulatory signals. UV exposure can enhance such hyposen- 
sitization. 
Objective: The aim of this study was to establish the capability of a hyposensitization pro- 
cedure to induce antigen-specific tolerance. 
Methods: Twenty-one patients with nickel ACD were randomly assigned to either a 
hyposensitized or control group. A schedule consisting of UVB treatment and subcutaneous 
nickel sulfate administration (hyposensitization) or WB only (control) was applied. During 
the ensuing 2 years, several clinical and immunologic features were monitored. 
Results: During UVB treatment we observed a significant clinical improvement in both 
groups that persisted in the hyposensitized group. Except for increased slope variances of 
specific lymphocyte proliferation in time, no clear changes were seen in the immunologic 
findings. 
Conclusion: Despite significant clinical improvement induced by UVB, hyposensitization did 
not induce significant changes in the immunologic findings in patients with nickel ACD. 
(JAM ACA~DERMATOL l%95;32:576-83.) 
The type of allergic contact dermatitis (ACD) 
most frequently diagnosed involves nickel allergy. 
Treatment of chronic ACD has been largely symp- 
tomatic because consistent avoidance of skin contact 
with and dietary intake of nickel are difficult to 
achieve. Allergen-specific T lymphocytes are crucial 
in the pathogenesis of ACD. Nickel-specific T lym- 
phocyte clones have been isolated from peripheral 
blood of nickel-allergic patients.lm4 When activated, 
these T lymphocytes produce interleukin 2 (IL-2) 
and high levels of interferon-y’? 4 and cause itiam- 
matory skin injury. Prevention of skin injury may be 
obtained through inhibition of specific T-cell activa- 
tion (e.g., through hyposensitization). 
A state of specific tolerance or anergy has been 
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described after antigen presentation in the absence 
of costimulatory signals.5-7 In both micesm21 and hu- 
man beings,5> 22 UVB induces specific hyporespon- 
siveness when administered simultaneously with al- 
lergen. UV exposure (even suberythemagenic doses) 
has significant down-modulatory effects on T cell- 
mediated responses to contact allergens. In a previ- 
ous study we demonstrated a clear effect of UVB on 
patch test responses to nickel, possibly through de- 
pletion of Langerhans cells (LC) and induction of 
CD1 a-DR+ antigen-presenting cells.5 
Until now, hyposensitization treatment has been 
restricted to immediate hypersensitivity reactions 
such as those to insect venoms and pollen. In view of 
the clear effects of UVB on LC and ACD, we 
designed a hyposensitization schedule that bypasses 
the highly sensitizing potential of epidermal LC by 
combining UVB treatment with subcutaneous in- 
jection of nickel sulfate solutions. 
MATERIAL AND METHODS 
Patch tests 
Before the start of the study a European standard patch 
test series of contact allergens (van der Bend, Brielle, The 
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Table I. Monoclonal antibodies used 
Antibody 
Leu-4 (FITC/PE) 
Leu-3 (FITC/PE) 
Leu- 1 
Leu-2 (PE) 
LFA1/2 
My4 
Leu-1 lc (PE) 
Bl (FITC) 
B4 (FITC) 
2A3 (PE) 
HLe- 1 
BBA4 
Leu-19 (PE) 
L243 (PE) 
CD code 
(antigen recognized) 
CD3 
CD4 
CD5 
CD8 
CD1 la 
CD14 
CD16 
CD19 
CD20 
CD25 
CD45 
CD54 
CD56 
HLA-DR 
Source 
Be&on Dickinson, Sunnyvale, Calif. 
Be&on Dickinson 
Be&on Dickinson 
Becton Dickinson 
CLB, Amsterdam, The Netherlands 
Coulter Clone, Hialeah, Fla. 
Becton Dickinson 
Coulter Clone 
Coulter Clone 
Becton Dickinson 
Be&on Dickinson 
British Biotechnology, Oxon, U.K. 
Be&on Dickinson 
Becton Dickinson 
CLB, Central Laboratory of the Red Cross Blood Transfusion Service; FZTC, fluorescein isothiocyanate; LFA, lymphocyte function-associated an- 
tigen; PE, phycoerythrin. 
Netherlands), including nickel sulfate, potassium dichro- 
mate, and cobalt chloride, was performed according to 
guidelines of the International Contact Dermatitis Re- 
search Group. After 48 hours the patch chambers were 
removed. At 48 and 72 hours the skin reaction was scored 
as described earlier.23 At the start of the study patch tests 
with nickel, chromium, and cobalt were repeated to ob- 
tain baseline values. Because of the risk of further sensi- 
tization or boostering, patch tests were not repeated. 
Patients 
Twenty-one patients allergic to nickel as judged by 
history and clinical signs of contact allergy (predomi- 
nantly on the hands and face) indicating nickel as a likely 
cause and confirmed by a patch test response of 2+ or 
greater to nickel sulfate were enrolled in and completed 
the study. All subjects were nonpregnant women. 
Each patient was randomly assigned to either the hy- 
posensitized group, scheduled for UVB plus nickel sulfate 
administration, or to the control group, which was to re- 
ceive only UVB treatment. The protocol and informed 
consent documents were approved by the committee on 
medical ethics of our hospital. The hyposensitized group 
consisted of 12 women, 28 + 5 years of age. Nine 
patients, 38 + 16 years of age, formed the control group. 
UVB treatment 
A Waldmann UV 1000 standing UV cabinet was used 
for UV treatment. All patients (hyposensitized and con- 
trol groups) received UVB pretreatment during the first 
3 to 6 months. On the basis of skin type, exposure started 
at 5 to 10 mJ/cm2 three times a week and gradually in- 
creased, allowing only mild erythema. Nickel sulfate in- 
jections were started in the hyposensitized group as soon 
as a cumulative dose of 1.0 J/cm2 was reached. At this 
point, UV exposure was continued once a week until a 
cumulative dose of approximately 1.25 mJ/cm2 was 
reached. 
Hyposensitization procedure 
Sterile, pyrogen-free solutions of 1 O@‘, 1 O@, 1 Op4, and 
1O-3 mol/L nickel sulfate were prepared. The lowest 
concentration equals the nickel concentration normally 
measured in body fluids.24-27 In a manner similar to hy- 
posensitization schedules used in type I allergy, weekly 
subcutaneous injections were started with 0.1 ml of the 
lowest nickel sulfate concentration in the arm. After each 
injection the patients were observed for at least 20 min- 
utes. If possible, the next doses were subsequently 0.2,0.4, 
0.7, and 1 .O ml of the same concentration, and finally 0.1 
ml of the next concentration. Doses were increased until 
either minimal local symptoms occurred or the highest 
concentration was reached. At this point the maximal 
dose achieved was continued and the interval was grad- 
ually prolonged up to 1 month. The total duration of the 
nickel sulfate hyposensitization was 2 years. 
Clinical evaluation 
The clinical follow-up period was 24 months. At three 
defined time points-at the start of the study (month 0), 
at maximal UVB exposure (month 6) and at the end 
(month 18) of the hyposensitization treatment-clinical 
evaluation was done. The affected area of involved skin, 
severity (itching, papules, vesicles, and fissure formation), 
frequency of symptoms, therapeutic need (use of corti- 
costeroids and its potency), and a subjective quality of life 
assessment were scored on a standard evaluation form. 
With respect to clinical scores, the control group consisted 
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Fig. 1. Time course of disease activity scores in hyposensitized (left panels) and control 
(right panels) groups with regard to affected area (A and B), severity (C and D), frequency 
(E and F) and therapy (G and H). 
of eight patients, because we excluded one patient because 
of lack of clinical follow-up information. 
Lymphocyte proliferation assays 
Lymphocyte proliferation assays (LPA) were per- 
formed as described earlier.23 Lymphocyte proliferation 
was expressed as counts per minute. Stimulation indices 
(SI) (i.e., relative proliferation) were calculated by divid- 
ing specific by background proliferation. In our labora- 
tory an SI greater than 3 was considered to be indicative 
of prior lymphocyte sensitization to nickel. 
Fluorescence-activated cell sorter 
immunophenotyping 
Peripheral blood samples were immunophenotyped 
with the monoclonal antibodies listed in Table I. Except 
Journal of the American Academy of Dermatology 
Volume 32, Number 4 Troost et al. 579 
1 95% interval 
I  I  
6 
time (tFonths) 
16 
I  
hyposens controls 
Fig. 2. Level of nickel reactivity in time as measured by nickel-specific lymphocyte prolif- 
eration. A, Mean SI values over time in all patients within each group. Bars represent 95% 
confidence intervals. B, Slopes of individual time plots as calculated by linear regression 
analysis. Closed circles, hyposensitized group; open circles, control group. 
for lymphocyte function-associated antigen (LFA)- l/2 
and BBA4, all monoclonal antibodies were directly con- 
jugated to either fluorescein isothiocyanate or phyco- 
erythrin. Measurement and analysis was done with a 
FACScan flow cytometer (Be&on Dickinson, San Jose, 
Calif.) with Simulset, FACScan, Consort 30, and Lysis 
research software (Be&on Dickinson, San Jose, Calif.). 
Both absolute cell numbers per microliter and percent- 
ages were calculated. 
Statistical analysis 
Professional STATA 3.0 Statistics/Data Analysis 
(Computing Resource Center, Santa Monica, Calif.) and 
EGRET (version 0.26.6, 1991, Serc and Cytel, Seattle, 
Wash.) were used for data analysis and statistical calcu- 
lations. 
The change of the disease activity scores during treat- 
ment was analyzed within each group with the Wilcoxon 
signed-rank test. An exact trend test was used to compare 
the hyposensitized and control groups with regard to the 
distribution of the scores at the end of the study. 
The distributions of SI and cell counts were trans- 
formed to normal by taking natural log values. This en- 
ables use of parametric statistical methods. The resulting 
distributions were checked for normality in normal plots. 
Linear regression was used to analyze time trends of 
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Table II. Distribution of lymphocyte phenotypes 
Nickel-allergic subjects 
Cell type Hyposensitized Control 
Lymphocytes 2.0(1.4-4.1) 1.3 (1.0-2.5) 
B cells 0.2 (0.08-0.4) 0.1 (0.05-0.2) 
T cells 1.4 (1.1-3.2) 1 .l (0.7-2.2) 
CD4 1.1 (0.6-2.5) 0.7 (0.5-1.4) 
CD8 0.5 (0.3-1.0) 0.3 (0.1-0.7) 
Natural killer cells 0.2 (0.08-0.3) 0.1 (0.1-0.2) 
Values are median absolute cell counts per milliliter; 95% confidence intervals shown in parentheses. 
Nonallergic controls 
1.7 (1.1-2.6) 
0.1 (0.1-0.2) 
1.2 (0.8-2.2) 
0.7 (0.4-l .5) 
0.4 (0.2-0.7) 
0.2 (0.06-0.6) 
lymphocyte proliferation and activated T-cell numbers 
during treatment.28 The resulting slope values of both 
groups were compared in a t test modified for unequal 
variances (Welch test). Equality of variances was tested 
in the variance ratio test (F test). 
RESULTS 
Baseline values of patch tests and LPA 
The distributions of baseline values for both patch 
tests and LPA in the hyposensitized and control 
groups were compared. Patch test scores and specific 
lymphocyte proliferation were comparable in both 
groups. In both the hyposensitized and the control 
groups a patient previously (before study) patch test 
reactive to nickel showed a negative baseline value 
of the patch test at the start of treatment. However, 
LPA results showed that lymphocyte reactivity to 
nickel still existed. 
UVB dose 
Individual UVB doses ranged between 5 and 50 
mJ/cm2. In both groups the cumulative dose of 1 .O 
J/cm2 was reached within the first 4 months. 
Nickel sulfate administration 
Most patients tolerated a lOO- to lOOO-fold in- 
crease of the nickel dose within 3 months. In two 
patients the maximum dose of 1 .O ml of 10m3 mol/L 
nickel sulfate was reached. Adverse effects remained 
limited to transient local induration that developed 
at the site of injection within 8 to 24 hours. These le- 
sions were histologically characterized by a perivas- 
cular accumulation of mononuclear cells. To avoid 
this reaction, doses were temporarily lowered. As a 
result, in some patients doses varied, occasionally by 
lo-fold, because of variable nickel tolerability. 
Clinical evaluation 
Fig. 1 shows dot plots of the four disease activity 
scores in both groups at three time points: at the start 
of the study (month 0), during maximal UVB expo- 
sure (month 6), and at the end of the study (month 
18). Overall, scores within both groups dropped 
during UVB treatment. This trend continued even 
after UVB exposure was stopped. In the hyposensi- 
tized group this led to p values of 0.0076, 0.0076, 
0.065, and 0.045 for the affected area, severity, fre- 
quency, and therapy scores respectively. In the con- 
trol group these p values were larger, namely, 0.02 1, 
0.021,0.94, and 0.14, respectively. The change of the 
disease activity scores was most evident for the 
affected area and severity scores. However, between 
the hyposensitized and control groups no statistically 
significant score differences were found (p = 0.84, 
0.33, 0.26, and 0.40, respectively). 
Lymphocyte proliferation 
Specific lymphocyte reactivity against nickel was 
monitored during the hyposensitization therapy. 
Within each patient some variation of SIs was found 
during the 2-year observation period. Neither SI nor 
net counts per minute values showed significant cor- 
relation with clinical scores. 
In Fig. 2, A, mean SI values and 95% confidence 
intervals of all patients within each group are plot- 
ted against duration of treatment. Mean prolifera- 
tion indices over time varied between 10 and 30. No 
significant difference was seen between the groups. 
In an attempt to characterize further the time course 
of lymphocyte reactivity, slopes of individual time 
plots were calculated by linear regression analysis. 
The resulting slope values indicate ascending or de- 
scending trends of lymphocyte reactivity with dura- 
tion of treatment. However, neither positive nor 
negative slope values corresponded with clinical im- 
provement. Fig. 2, B, shows approximately equiva- 
lent mean slope values but increased slope variance 
in the hyposensitized group as compared with con- 
trol subjects. This difference of variances was highly 
significant (p < 0.001). 
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Fig. 3. Mean CD3+/IL-2 receptor+ (A)and CD3+/HLA-DR+ (B)cellnumbers over time 
in all patients within each group. Bars represent 95% confidence intervals. Closed circles, hy- 
posensitized group; open circles, control group. 
Fluorescence-activated cell sorter 
immunophenotyping 
Numbers of B cells, T cells (including the sub- 
populations), and natural killer cells were within 
normal limits, comparable in both groups, and fairly 
constant over time (Table II). 
In an attempt to characterize further the nickel- 
reactive lymphocytes, we did flow cytometric anal- 
ysis of peripheral blood mononuclear cells for acti- 
vated T cells with CD3/HLA-DR and CD3/CD25 
double staining. Actual double-positive cell numbers 
per microliter were calculated and plotted against 
time. Values ranged from 10 to 1000 cells/y1 in both 
groups. Fig. 3 shows the time course of mean 
CD3+/IL-2 receptor+ and CD3+/HLA-DRf cell 
counts and 95% confidence intervals of all patients 
within each group. On average, CD25’ counts were 
1.7 times higher than HLA-DRf counts. As previ- 
ously described,29 coexpression of IL-2 receptor and 
HLA-DR on T cells is limited. Apparently these 
markers represent at least partially different types or 
phases of activation. The average number of acti- 
vated T cells was estimated at approximately 100 to 
150 cells/p1 (i.e., 5% to 20% of circulating T cells). 
These values are within normal limits. 
LFA- 1 a and intercellular adhesion molecule1 
expression of both peripheral blood lymphocytes and 
monocytes was also measured. Lymphocytes showed 
582 Troost et al. 
a bimodal LFA- la expression, that is, normal 
(LFA- If) and high (LFA- I++), mainly because of 
the expression of this molecule on T cells. During the 
study these two levels of expression appeared to be 
inversely correlated. These time trends, however, did 
not match clinical disease activity. 
DISCUSSION 
Hyposensitization with contact allergens has pre- 
viously been shown to be elYective.30-34 The present 
study describes monitoring of clinical and immuno- 
logic features during such nickel hyposensitization. 
Considerable clinical improvement was observed 
during UVB pretreatment. In both groups this trend 
persisted even after UVB withdrawal. No statisti- 
cally significant difference between the groups was 
seen. 
Lymphocyte reactivity to nickel appeared to fluc- 
tuate with time. Height of SI showed no correlation 
with clinical scores. Discordance between clinical 
and in vitro findings has previously been de- 
scribed.35-40 
Overall, no significant change in the in vitro lym- 
phocyte reactivity to nickel was seen during the 
monitored period. However, time-trend analysis of 
each patient revealed a significantly larger slope 
variabilitywithinthehyposensitizedgroup. Itsmean- 
ing is not entirely clear. Possibly the effect of 
hyposensitization varies in different persons21* 41 
Activated T lymphocytes in peripheral blood, mea- 
sured as CD3+/HLA-DR+ and CD3+/CD25+ 
cells, remained within normal limits during treat- 
ment. It is conceivable that the number of nickel- 
specific memory T lymphocytes is too low to allow 
detection of changes in the peripheral circulation. 
As in type I hyposensitization, the mechanisms by 
which clinical improvement might be explained re- 
main to be elucidated. Evidence is emerging that 
besides LC and T lymphocytes, keratinocytes are 
also actively involved in immunologic reactions in 
the skin. Insight into the process of induction of cen- 
tral or peripheral tolerance, clonal anergy, or active 
suppression is only beginning to appear.42-45 Analy- 
sis of epidermal cells and lymphocytes for the pres- 
ence and susceptibility of costimulatory factors, such 
as adhesion molecules46-48 and cytokineq7> 49, 5o and 
the influence of immunomodulators such as UV ra- 
diation on these, may provide more insight into this 
process. 
We thank Rene van den Beemd, Lidy Geursen- 
Reitsma, and Tar van OS for their assistance in fluores- 
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cence-activated cell sorter analysis, patch testing, and 
preparation of the graphs, respectively. 
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